

**In the Claims:**

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 14, 18, 20, 21, 25, 27, and 31-36 without prejudice to their presentation in another application as follows:

1-11. (canceled).

12. (previously presented) A composition comprising a peptide consisting of the sequence MILNSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSHFV VGIFG (SEQ ID NO:1), in which the peptide is conjugated to a carrier protein.

13-18. (canceled).

19. (previously presented) A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide, wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

20-25. (canceled).

26. (previously presented) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide, wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

27. (canceled).

28. (previously presented) The composition of claim 12 further comprising an adjuvant.

29-36. (canceled).